Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin, Dr Reddy's...

    Lupin, Dr Reddy's recall 1.7 lakh bottles of tablets in US

    Written by savita thakur thakur Published On 2016-07-07T15:06:57+05:30  |  Updated On 7 July 2016 3:06 PM IST
    Lupin, Dr Reddys recall 1.7 lakh bottles of tablets in US

    New Delhi : Drug majors Lupin and Dr Reddy's are recalling over 1.7 lakh bottles of two different tablets, used in the treatment of blood pressure and acidity, in the US due to deviations from manufacturing norms.


    According to the latest Enforcement Report of United States Food and Drug Administration (USFDA) Lupin's US arm Lupin Pharmaceuticals Inc is recalling 59,520 bottles of Lisinopril & Hydrochlorothiazide tablets USP 20mg/12.5mg, 5,880 bottles of Lisinopril tablets, USP 40 mg and 20,587 bottles of Lisinopril tablets, USP 30mg due to deviation from current good manufacturing practice (CGMP).


    The "finished products (were) manufactured using active pharmaceutical ingredients whose intermediates failed specifications," the report said, adding the ongoing nation wide recall is also being carried out in Puerto Rico.


    As per the report, the recall is a class III recall which is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences."


    The drugs are manufactured at the company's Pithampur plant in Madhya Pradesh.


    In case of Dr Reddy's Laboratories, its US arm Dr Reddy's Laboratories Inc, is recalling 84,240 bottles of Famotidine 10 mg tablets.


    On the reason of the recall, the report mentioned that "an out of specification results has been determined for an individual related substance during stability testing at the 18th month interval for the tablet".


    It is an class III recall, the Enforcement Report said.

    blood pressurecGMPcurrent good manufacturing practiceDr Reddy'sEnforcement ReportLisinopril & HydrochlorothiazideLupinPuerto RicoUS Food & Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok